Marburgvirus Infections Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Marburgvirus Infections

September 2018 | 65 pages | ID: M823129F722EN
VPAResearch

Abstracts

Marburgvirus Infections Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Marburgvirus Infections Infection pipeline products.

DISEASE OVERVIEW

Marburgvirus Infections infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

REPORT DESCRIPTION

The Marburgvirus Infections Infection pipeline guide presents complete overview of drugs currently being developed for Marburgvirus Infections Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Marburgvirus Infections Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Marburgvirus Infections Infection pipeline candidates is included.

Major companies participating in therapeutic development of Marburgvirus Infections Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Marburgvirus Infections Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Marburgvirus Infections Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Marburgvirus Infections Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF MARBURGVIRUS INFECTIONS INFECTION PIPELINE REPORT INCLUDES

• Panorama of Marburgvirus Infections Infection pipeline markets including statistics on therapeutic drugs and companies involved
• Marburgvirus Infections Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Marburgvirus Infections Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Marburgvirus Infections Infection pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Marburgvirus Infections Infection pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Marburgvirus Infections Infection pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Marburgvirus Infections Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Marburgvirus Infections Infection Pipeline include
  Number of Companies with Marburgvirus Infections Infection projects in pre-clinical Development
  Number of Companies with Marburgvirus Infections Infection projects in Clinical Development
  Marburgvirus Infections Infection Pipeline Companies based in Americas
  Marburgvirus Infections Infection Pipeline Companies based in Europe
  Marburgvirus Infections Infection Pipeline Companies based in Asia Pacific
  Marburgvirus Infections Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  Marburgvirus Infections Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
  Marburgvirus Infections Infection Pipeline Agents in Clinical Development stage
  Marburgvirus Infections Infection Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the Marburgvirus Infections Infection Pipeline agents

II. INSIGHTS INTO MARBURGVIRUS INFECTIONS INFECTION PIPELINE

1. Disease Overview
  Introduction to Marburgvirus Infections Infection
  Symptoms and Causes of Marburgvirus Infections Infection
  Treatment or Prevention Options for Marburgvirus Infections Infection
  Other Details
2. Phase wise Pipeline Compounds
  Marburgvirus Infections Infection Pipeline Pre- Clinical/Discovery stage Drugs
  Marburgvirus Infections Infection Pipeline Phase 1 stage Drugs
  Marburgvirus Infections Infection Pipeline Phase 2 stage Drugs
  Marburgvirus Infections Infection Pipeline Phase 3 stage Drugs
  Marburgvirus Infections Infection Pipeline Pre-Registration stage Drugs
3. Company wise Marburgvirus Infections Infection Pipeline Compounds
4. Marburgvirus Infections Infection Pipeline by Mechanism of Action

III. MARBURGVIRUS INFECTIONS INFECTION PIPELINE COMPOUND DETAILS

MVA-BN Filo multivalen
BCX4430
Pan filovirus
filovirus vaccine
Quinoxaline-based inhibitors of Ebola and Marburg VP40
GEO-EM05
trivalent Ebola-Marburg vaccine
Marburg VLP Vaccine
Bispecific Antibodies for Ebola and Marburg
MBP091
Small Molecules for Ebola/Marburg
PBI-05204
VesiculoVax monovalent vaccine
VesiculoVax trivalent vaccine
TargoVir
Drug Details
  1. Snapshot
    Name of the Therapeutic Agent
     Originator
    Developing Company
    Co-Developer/License Partner
    Orphan Drug/Fast Track/Designation
    Development Phase
  2. Drug Overview
  3. Mechanism of Action
  4. Current Status
  5. Clinical Trial Details

IV. MARBURGVIRUS INFECTIONS INFECTION PIPELINE COMPANY BRIEFS

Bavarian Nordic
BioCryst Pharmaceuticals Inc
Emergent BioSolutions Inc
Emergex Vaccines
Fox Chase Chemical Diversity Center Inc.
GeoVax Labs Inc
Greffex Inc
Integrated BioTherapeutics Inc
Integrated BioTherapeutics Inc
Mapp Biopharmaceutical Inc
NanoViricides Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MARBURGVIRUS INFECTIONS INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability